HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Albee Messing Selected Research

Glial Fibrillary Acidic Protein

3/2021Pexidartinib treatment in Alexander disease model mice reduces macrophage numbers and increases glial fibrillary acidic protein levels, yet has minimal impact on other disease phenotypes.
1/2020Type II Alexander disease caused by splicing errors and aberrant overexpression of an uncharacterized GFAP isoform.
12/2019Refining the concept of GFAP toxicity in Alexander disease.
10/2018Mutations in GFAP Disrupt the Distribution and Function of Organelles in Human Astrocytes.
1/2018Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease.
1/2017Glial fibrillary acidic protein exhibits altered turnover kinetics in a mouse model of Alexander disease.
1/2015Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease.
1/2015CSF and Blood Levels of GFAP in Alexander Disease
9/2014Effects of traumatic brain injury on reactive astrogliosis and seizures in mouse models of Alexander disease.
5/2014Astrocytic TDP-43 pathology in Alexander disease.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Albee Messing Research Topics

Disease

33Alexander Disease (Alexander's Disease)
11/2021 - 03/2005
9Neurodegenerative Diseases (Neurodegenerative Disease)
11/2021 - 03/2004
6Nervous System Diseases (Neurological Disorders)
02/2016 - 03/2005
5Gliosis
01/2019 - 02/2003
4Seizures (Absence Seizure)
01/2019 - 10/2006
2Body Weight (Weight, Body)
03/2021 - 08/2012
2Wounds and Injuries (Trauma)
01/2019 - 09/2013
2Brain Diseases (Brain Disorder)
01/2018 - 08/2005
2Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
05/2014 - 12/2008
2Charcot-Marie-Tooth Disease (Peroneal Muscular Atrophy)
07/2006 - 02/2005
2Peripheral Nervous System Diseases (PNS Diseases)
07/2006 - 01/2002
2Muscular Dystrophies (Muscular Dystrophy)
07/2002 - 01/2002
1Inborn Genetic Diseases (Disease, Hereditary)
12/2016
1Leukoencephalopathies
04/2015
1Frontotemporal Dementia (Semantic Dementia)
05/2014
1Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar)
05/2014
1Intellectual Disability (Idiocy)
11/2013
1Brain Injuries (Brain Injury)
05/2011
1Hypoxia (Hypoxemia)
05/2011
1Ischemia
05/2011
1Schizophrenia (Dementia Praecox)
12/2010
1AIDS-Related Complex (ARC)
12/2010
1Brain Edema (Cerebral Edema)
08/2010
1Inflammation (Inflammations)
12/2007
1HIV Infections (HIV Infection)
12/2007
1Demyelinating Diseases (Demyelinating Disease)
02/2006
1Acute-Phase Reaction
08/2005
1Astrocytoma (Pilocytic Astrocytoma)
08/2005
1Brain Neoplasms (Brain Tumor)
08/2005
1Neuromuscular Diseases (Neuromuscular Disease)
06/2003

Drug/Important Bio-Agent (IBA)

20Glial Fibrillary Acidic ProteinIBA
03/2021 - 03/2005
15Proteins (Proteins, Gene)FDA Link
03/2021 - 08/2005
4Protein AggregatesIBA
11/2013 - 03/2005
3Kainic Acid (Kainate)IBA
01/2019 - 10/2006
2Antisense OligonucleotidesIBA
11/2021 - 01/2018
2CytokinesIBA
03/2021 - 08/2005
2Messenger RNA (mRNA)IBA
01/2020 - 01/2013
2Protein Isoforms (Isoforms)IBA
01/2020 - 05/2011
2AntioxidantsIBA
08/2012 - 01/2012
2ConnexinsIBA
07/2006 - 02/2005
2Mutant Proteins (Protein, Mutant)IBA
02/2006 - 08/2005
2Complement System Proteins (Complement)IBA
08/2005 - 03/2004
2Dystroglycans (Dystroglycan)IBA
06/2003 - 07/2002
1ChemokinesIBA
03/2021
1pexidartinibIBA
03/2021
1Transcription Factor AP-1 (Transcription Factor AP 1)IBA
01/2019
1Biological ProductsIBA
01/2018
1LaminsIBA
01/2018
1Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA
02/2016
1Cholinergic Agents (Cholinergics)IBA
02/2016
1Cholinergic ReceptorsIBA
02/2016
1Nitric Oxide (Nitrogen Monoxide)FDA Link
11/2015
1LithiumIBA
01/2015
1DNA-Binding Proteins (DNA Binding Protein)IBA
05/2014
1Indicators and Reagents (Reagents)IBA
01/2013
1Glutathione (Reduced Glutathione)IBA
08/2012
1Neuroprotective AgentsIBA
08/2012
1Glutamate-Cysteine LigaseIBA
08/2012
1Transcription Factors (Transcription Factor)IBA
01/2012
1Sodium-Hydrogen ExchangersIBA
05/2011
1Serine (L-Serine)FDA Link
12/2010
1N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
12/2010
1N-Methylaspartate (NMDA)IBA
12/2010
1Inositol (Myoinositol)IBA
08/2010
1TaurineFDA Link
08/2010
1Glucose (Dextrose)FDA LinkGeneric
08/2010
1Acetates (Acetic Acid Esters)FDA Link
08/2010
1Glutamic Acid (Glutamate)FDA Link
04/2010
1Crystallins (Crystallin)IBA
04/2009
1Superoxide Dismutase-1IBA
12/2008
1p38 Mitogen-Activated Protein KinasesIBA
06/2008
1Ginkgo biloba extract (Rokan)IBA
12/2007
1Potassium Channels (Potassium Channel)IBA
09/2007
1Cytokine Receptors (Cytokine Receptor)IBA
08/2005
1DNA (Deoxyribonucleic Acid)IBA
03/2005
1Ferritins (Ferritin)IBA
03/2004
1DystrophinIBA
06/2003
1Glycoproteins (Glycoprotein)IBA
06/2003
1Connexin 43 (Connexin43)IBA
02/2003
1IntegrinsIBA
01/2002
1Laminin (Merosin)IBA
01/2002

Therapy/Procedure

4Therapeutics
11/2021 - 08/2005